Reuters logo
4 个月前
BRIEF-Cerenis Therapeutics says primary endpoint not met in CARAT phase 2 study
2017年3月20日 / 上午10点29分 / 4 个月前

BRIEF-Cerenis Therapeutics says primary endpoint not met in CARAT phase 2 study

1 分钟阅读

March 20 (Reuters) - Cerenis Therapeutics Holding SA :

* Cerenis therapeutics announces that CARAT phase 2 study data on CER-001 have been presented at ACC annual meeting 2017

* Primary endpoint, regression of coronary plaque in ACS, not met

* Safety profile of CER-001 is reinforced

* Tango phase 3 clinical study in patients with genetic HDL deficiencies is ongoing

* Negative results encountered with CER-001 were not consistent with previously reported efficacy profile of CER-001 in 3mg/kg subgroup of chi square clinical study Source text for Eikon: Further company coverage: (Gdynia Newsroom:)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below